Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.41
NEPT's Cash-to-Debt is ranked lower than
90% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NEPT: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
NEPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.75 Max: No Debt
Current: 0.41
Equity-to-Asset 0.62
NEPT's Equity-to-Asset is ranked lower than
60% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NEPT: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
NEPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.55 Max: 0.83
Current: 0.62
-0.42
0.83
Debt-to-Equity 0.36
NEPT's Debt-to-Equity is ranked lower than
61% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NEPT: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
NEPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.59  Med: 0.38 Max: 21.54
Current: 0.36
-9.59
21.54
Interest Coverage 0.87
NEPT's Interest Coverage is ranked lower than
98% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NEPT: 0.87 )
Ranked among companies with meaningful Interest Coverage only.
NEPT' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.87
Piotroski F-Score: 6
Altman Z-Score: 0.58
Beneish M-Score: -1.76
WACC vs ROIC
6.60%
2.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 5.34
NEPT's Operating Margin % is ranked higher than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NEPT: 5.34 )
Ranked among companies with meaningful Operating Margin % only.
NEPT' s Operating Margin % Range Over the Past 10 Years
Min: -262.75  Med: -27.32 Max: -9.17
Current: 5.34
-262.75
-9.17
Net Margin % 5.55
NEPT's Net Margin % is ranked higher than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NEPT: 5.55 )
Ranked among companies with meaningful Net Margin % only.
NEPT' s Net Margin % Range Over the Past 10 Years
Min: -185.54  Med: -34.74 Max: -10.08
Current: 5.55
-185.54
-10.08
ROE % 10.06
NEPT's ROE % is ranked higher than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NEPT: 10.06 )
Ranked among companies with meaningful ROE % only.
NEPT' s ROE % Range Over the Past 10 Years
Min: -596.63  Med: -40.12 Max: -9.66
Current: 10.06
-596.63
-9.66
ROA % 2.22
NEPT's ROA % is ranked higher than
87% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NEPT: 2.22 )
Ranked among companies with meaningful ROA % only.
NEPT' s ROA % Range Over the Past 10 Years
Min: -34.21  Med: -21.42 Max: -5.71
Current: 2.22
-34.21
-5.71
ROC (Joel Greenblatt) % 3.78
NEPT's ROC (Joel Greenblatt) % is ranked higher than
77% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NEPT: 3.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NEPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -80.32  Med: -32.38 Max: -10.19
Current: 3.78
-80.32
-10.19
3-Year Revenue Growth Rate -20.20
NEPT's 3-Year Revenue Growth Rate is ranked lower than
70% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NEPT: -20.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NEPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.35 Max: 30.5
Current: -20.2
0
30.5
3-Year EBITDA Growth Rate 57.90
NEPT's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NEPT: 57.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NEPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.4  Med: 27.6 Max: 219.3
Current: 57.9
-34.4
219.3
3-Year EPS without NRI Growth Rate 111.80
NEPT's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NEPT: 111.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NEPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 11.4 Max: 200
Current: 111.8
-48.9
200
GuruFocus has detected 2 Warning Signs with Neptune Technologies & Bioressources Inc $NEPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NEPT's 30-Y Financials

Financials (Next Earnings Date: 2017-10-12 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NEPT Guru Trades in

NEPT Guru Trades in

NEPT Guru Trades in

Q2 2015

NEPT Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3741
Compare:TSX:CXR, TSX:ONC, TSX:HBP, TSXV:TBP, TSXV:ABCN, NAS:XENE, TSX:COM, TSXV:COV, TSX:TRIL, XCNQ:CRZ, NAS:SRRA, XCNQ:THC, OTCPK:IGXT, TSXV:EMH, TSXV:BTI, TSX:APS, TSXV:CZO, XCNQ:VGW, TSXV:EMC, TSXV:IPA » details
Traded in other countries:NEPT.Canada, NTU.Germany,
Headquarter Location:Canada
Neptune Technologies & Bioressources Inc is a nutrition products company engaged in customizing nutrition solutions, specialty ingredients and consumer brands. It offers premium krill oil under OCEANO3 and other ingredients such as marine and seed oils.

Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It operates in Nutraceutical and Cardiovascular segment. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.

Top Ranked Articles about Neptune Technologies & Bioressources Inc

Neptune and Enzymotec Reach Patent Agreement Ending All Litigation
Acasti Pharma Reports Second Quarter 2017 Financial Results

Key Developments Include New Leadership and Advancement of Drug Candidate CaPre

LAVAL, QUEBEC--(Marketwired - Oct 11, 2016) - Acasti Pharma (NASDAQ:ACST)(TSX VENTURE:APO) today announced its operating and financial results for the second quarter of its 2017 fiscal year, which ended August 31, 2016. All amounts are in Canadian dollars. "During our second fiscal quarter, we continued to improve our business operations while simultaneously building the value of our drug candidate CaPre® by advancing it towards late-stage development," said Jan D'Alvise, president and CEO of Acasti Pharma. "Last month we reported positive results from our bridging study and believe the data supports the 505(b)(2) regulatory pathway chosen by Acasti to gain U.S. marketing approval of CaPre for the treatment of patients with severe hypertriglyceridemia. We look forward to working with the FDA to confirm the pathway and optimize the design of our Phase 3 program, which we expect to begin before the end of next year." Second Quarter 2017 and Year-to-Date Financial Results(1)

Research and development (R&D) expenses were $1.6 million for the second quarter, down from $1.7 million in the second quarter of fiscal 2016. For the first six months of fiscal 2017, R&D expenses were $4.0 million, an increase from $3.6 million for the same period last year, attributed to increased expenses for the bridging study and Phase 3 study preparations.
General and administrative (G&A) expenses were $0.9 million for the second quarter, up from $0.5 million in the second quarter of fiscal 2016. For the first six months of fiscal 2017, G&A expenses were $1.4 million, an increase from $1.1 million for the same period last year. The current year's higher G&A expenses are attributed to increases in consulting services, business development activities, and compensation.
Non-IFRS operating loss(2) was $1.6 million for the second quarter, compared to $1.5 million in the second quarter of last year. For the first six months of fiscal 2017, the Non-IFRS operating loss was $3.9 million, an increase from $3.4 million for the same six-month period of last year.
Net loss was $2.3 million or $0.22 loss per share for the second quarter, compared to a net loss of $1.2 million or $0.12 loss per share in the second quarter of last fiscal year. Net loss was $5.5 million or $0.51 loss per share for the first six months of fiscal 2017, compared to a net loss of $2.2 million or $0.21 loss per share for the same period of the last fiscal year. The higher net loss for the current quarter reflects the $0.4 million increased G&A expenses combined with a decrease of $0.9 million in foreign exchange gain for the current year, offset by the $0.1 million decreased R&D expenses in the current year. The higher net loss for the current six-month period was primarily based on the increased R&D and G&A expenses, as well as a $1.6 million incremental decreased value of derivative warrant liabilities, and a $1.1 million change from a foreign exchange gain last year to a foreign exchange loss in the current year.
Cash and short-term investments of $8.1 million as of August 31, 2016 including $1.0 million in restricted short-term investments fully released on September 20, 2016.

Cash Flows With cash and short-term investments of $8.1 million as of August 31, 2016, if Acasti does not raise additional funds, there exists a material uncertainty that casts substantial doubt about the corporation's ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business. Management has reasonable expectation that the corporation will be able to raise additional funds. Key Developments

On September 14, 2016, Acasti announced positive data from its bioavailability study that compared CaPre (omega-3 free fatty acid/phospholipid composition) with the approved hypertriglyceridemia drug LOVAZA (omega-3-acid ethyl esters) in healthy volunteers. The study met its primary objective and demonstrated that the levels of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), following administration of CaPre did not exceed the levels following administration of LOVAZA in subjects who were fed a high-fat meal. In addition, among subjects in the fasting state, CaPre demonstrated better bioavailability than LOVAZA, as measured by blood levels of EPA and DHA. The study results are expected to support Acasti's plan to request authorization to use the FDA's 505(b)(2) pathway, enabling the company to streamline its development program required to support a New Drug Application (NDA) by relying on the safety data of an approved drug.
Acasti appointed Jan D'Alvise as president and chief executive officer effective June 1, 2016. D'Alvise is an accomplished executive with experience in large, public multi-national companies, as well as in private start-ups in the life sciences industry. Her track-record includes leadership roles across the enterprise life-cycle, from start-up to commercialization and growth.
A new board of directors was elected at the Annual and Special Meeting of Shareholders in July, including D'Alvise, Jean-Marie (John) Canan, Roderick N. Carter, James S. Hamilton, and Leendert H. Staal.
Acasti initiated the process leading to the cGMP manufacturing of CaPre for the planned Phase 3 clinical trial with qualified and experienced pharmaceutical CMO partners.
Acasti completed primary market research with Key Opinion Leaders (KOLs) and payers to support the CaPre development and commercialization strategy.

Future Corporate Milestones

Complete the protocol and planning of the CaPre Phase 3 clinical trial in patients with severe hypertriglyceridemia in the first half of calendar year 2017, including an End-of-Phase 2 meeting with the FDA.
Complete the scale-up of the manufacturing process of CaPre under cGMP conditions in the first half of calendar year 2017, and complete the production of the clinical trial product for the initiation of the Phase 3 clinical trial.
Initiate the Phase 3 clinical study for CaPre in patients with severe hypertriglyceridemia during the second half of calendar year 2017.

About CaPre CaPre is a novel composition of omega-3s (delivered both as free fatty acids and bound to phospholipids) sourced from krill oil. Acasti has successfully completed Phase 2 clinical trials for the treatment of hypertriglyceridemia, a very common metabolic condition in which blood levels of triglycerides, a type of lipid, are significantly elevated, posing a risk to cardiovascular health. Acasti plans to conduct a pivotal Phase 3 trial in patients with severe hypertriglyceridemia to support a New Drug Application filing for CaPre. Severe hypertriglyceridemia affects about 3 to 4 million adults in the U.S.(3) and is associated with an increased risk of coronary artery disease and pancreatitis and is often caused or exacerbated by uncontrolled diabetes mellitus, obesity and sedentary habits. CaPre is intended to be taken orally once per day in capsule form. About Acasti Pharma Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population(4). The company's strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can address patients' complete lipid profile, making a positive impact on the major lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com. Caution Regarding Non-IFRS Financial Measures The Corporation uses adjusted financial measures, including Non-IFRS operating loss (loss from operating activities before interest, taxes, depreciation and amortization, and other non-monetary expenses), to assess its operating performance. These Non-IFRS financial measures are directly derived from the Corporation's financial statements and are presented in a consistent manner. The Corporation uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Corporation to plan and forecast for future periods as well as to make operational and strategic decisions. The Corporation believes that providing this information to investors, in addition to IFRS measures, allows them to see the Corporation's results through the eyes of management, and to better understand its historical and future financial performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Non-IFRS operating loss to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in its operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results. Acasti's method for calculating Non-IFRS operating loss may differ from that used by other corporations. Acasti calculates its Non-IFRS operating loss measurement by adding to net loss, finance costs, depreciation and amortization and by subtracting finance income. Other items that do not impact core operating performance of the Corporation are excluded from the calculation as they may vary significantly from one period to another. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivative warrant liabilities. Acasti also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, from its Non-IFRS operating loss calculation. The Corporation believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is necessarily non-recurring. Forward-Looking Statements Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at www.acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors." Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.






RECONCILIATION OF NET LOSS TO NON-IFRS OPERATING LOSS



(Expressed in millions of dollars)










Three-month periods ended
Six-month periods ended



August 31, 2016

August 31, 2015

August 31, 2016

August 31, 2015




$

$

$

$



Net loss
(2.3
)
(1.2
)
(5.5
)
(2.2
)


Add (deduct):











Finance costs
-

-

0.3

0.1




Finance income
-

(0.9
)
(0.1
)
(0.9
)



Change in fair value of derivative warrant liabilities
(0.1
)
-

(0.1
)
(1.7
)



Depreciation and amortization
0.6

0.6

1.2

1.2




Stock-based compensation
0.2

-

0.3

0.1



Non-IFRS operating loss
(1.6
)
(1.5
)
(3.9
)
(3.4
)




(1) The quarterly unaudited financial statements with footnotes and the MD&A are available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at www.acastipharma.com. (2) See comment on Non-IFRS financial measures and the summary table, both of which follow. (3) Source: Am J Med. 2014, 127, 36-44 (4) Source: Datamonitor and Archives of Internal Medicine, 2009; 169(6):572-578





Acasti Contact:
Jan D'Alvise
Chief Executive Officer
450-686-4555
[email protected]
www.acastipharma.com




Read more...
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil®

A Unique ingredient for enhanced bioavailability

LAVAL, QUEBEC--(Marketwired - Oct 7, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB) through its wholly-owned subsidiary, Biodroga Nutraceutical Inc., has signed an exclusive, worldwide and royalty bearing commercial agreement with Ingenutra Inc. for its patented and clinically studied MaxSimil specialty ingredient. Designed as a unique delivery system, MaxSimil allows for enhanced bioavailability and absorption of lipid based and lipid soluble nutraceuticals ingredients such as omega-3 fish oils, vitamin A, D, K and E, CoQ10 and others. The agreement allows Neptune to manufacture, distribute and sell MaxSimil in the nutraceutical field worldwide. The terms also cover potential collaboration between both companies on clinical trials. The agreement is valid until 2028 and supersedes a previous arrangement between Biodroga and Ingenutra that was limited to North America. All other terms of the agreement remain confidential. Francois-Karl Brouillette, Vice-President Scientific Affairs of Neptune stated, "Increasing the bioavailability and absorption of EPA and DHA in a natural way is truly amazing. MaxSimil now makes it possible for everyone, including people suffering from compromised digestive health to properly assimilate their healthy fats. We are very proud to make this ingredient accessible worldwide. This is what Neptune and our industry are all about: improving the quality of life of consumers through healthy nutrition solutions." Serge Brunet, President of Ingenutra added, "I am proud of this new partnership with Neptune. I am confident that they will provide the steppingstone that will allow the benefits of MaxSimil to be recognized worldwide through Neptune's well established and growing network". Recently, one of Neptune's clients, XYMOGEN®, launched the MonoPure™ line of omega-3 EPA DHA products based on Maxsimil. It is aimed at the practitioner market in the United States. About Maxsimil The research and development of MaxSimil was developed by a researcher at the University of Rimouski, Quebec. MaxSimil mimics the natural digestive process and delivers a patented pre-digested and absorption-ready Monoglyceride-rich Omega-3 Fish Oil. It enhances the bioavailability and absorption of Omega-3 fatty acids by applying a natural and gentle enzymatic process converting them into pre-digested natural Monoglycerides. A human pharmacokinetic study has demonstrated with statistical significance 3x greater absorption of MaxSimil EPA and DHA when compared to a regular fish oil. Furthermore, this absorption ready omega-3 supplement is an ideal solution for populations in certain age groups, taking medication or suffering from conditions compromising their digestion health and preventing them to properly digest healthy fats. MaxSimil is a 100% natural fish oil with no additives. About Neptune Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers a variety of specialty ingredients, including premium krill oil manufactured in our state-of-the art facility and a variety of other marine oils, seed oils and specialty ingredients. Neptune also offers its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. Oceano3 brand is also sold in bulk to unbranded distributors. The Company's head office is located in Laval, Quebec. Page 2 of 2 Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 48% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. About Ingenutra INGENUTRA is a privately held, Sherbrooke based, B2B ingredient technology company focused on developing, manufacturing, and commercializing scientifically validated, natural active ingredients that aim to improve human and animal health. MaxSimil is Ingenutra's first novel delivery platform based on a patented technology that naturally enhances the absorption of lipid-based and lipid-soluble nutraceutical and pharmaceutical actives, such as omega-3s.





Mario Paradis
VP & CFO
1.450.687.2262
[email protected]
http://neptunecorp.com/
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]
James Carbonara
Hayden IR
1.646.755.4712
[email protected]




Read more...
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and Ending All Litigation

LAVAL, QUEBEC and OSLO, NORWAY--(Marketwired - Oct 3, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NTB) and Aker BioMarine ("Aker") are pleased to jointly announce that they have entered into a broad patent cross-licensing agreement, thus ending all outstanding litigation between both companies. Key elements of the settlement and licensing agreement:

Agreement ends all outstanding litigation, with continued access for Aker to Neptune's composition patents, in consideration of a royalty payment of US$10 million payable over a period of 15 months.
Neptune acquires rights to use Aker's select krill oil-related patent portfolio in consideration of a royalty payment of $US4 million payable over the same 15-month period.

"We are pleased that through this agreement the integrity of each company's Intellectual Property (IP) is recognized and puts an end to all legal challenges. Our collective focus can now be even more directed to the growth and development of the omega-3 krill oil market," stated Jim Hamilton, President & CEO of Neptune. "Recognition and protection of intellectual property is critical to continue to invest in innovation and R&D, which is key to driving growth in the krill oil industry. This joint patent agreement signifies the importance of respecting IP, further strengthening our position as the leading innovators in the global krill oil market," Matts Johansen, CEO, Aker BioMarine commented. This agreement should create a lasting patent peace, allowing both companies to focus on growth and business value creation. About Neptune Technologies & Bioressources Inc.
Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers premium krill oil manufactured in our state-of-the art facility and a variety of other specialty ingredients such as marine and seed oils. Neptune offers its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. Oceano3 brand is also sold in bulk to unbranded distributors. The Company's head office is located in Laval, Quebec. Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 48% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. About Aker BioMarine
Aker BioMarine is a leading supplier of krill-derived products to the consumer health and wellness and animal nutrition markets. For the consumer market, Aker BioMarine offers Superba™ Krill, which is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of SuperbaTM Krill is that the omega-3 fatty acids are provided in phospholipid form. In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of Superba™ Krill. For the animal nutrition market, Aker BioMarine offers QRILL™ Pet, which allows dogs and cats to benefit from the same health promoting krill-omega-3s as their pet parents. Health promoting nutrition for pets is lifted to a new level by the inclusion of the superior krill omega-3s known from human supplements like MegaRed. In 2015, Aker BioMarine launched Flexitech™, a new technology that enables Aker BioMarine to further expand the product line and bring ongoing innovation to the krill oil market. Aker BioMarine is dedicated to the sustainable fishing of krill and development of krill-derived products. The company supplies biomarine ingredients through a 100% traceable supply chain that it also owns and controls. Further, it is certified by the Marine Stewardship Council (MSC) for sustainability and traceability. Forward Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune and Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labelled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form (the "AIF"), which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunecorp.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.





Katrin Berntsen
Director Communication, Aker BioMarine
47 92054570
[email protected]
Mario Paradis
VP & CFO, Neptune
450-687-2262 x236
[email protected]




Read more...
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 2016

LAVAL, QUEBEC--(Marketwired - Sep 28, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on October 12, 2016 at 5:00 PM (EST) to discuss its second quarter results for the period ended August 31, 2016.
The second quarter results press release will be issued after markets close on the same day.


Conference Call Details:







Date:
Wednesday, October 12, 2016






Time:
5:00 PM Eastern Standard Time






Call:
1‐877-223-4471 (within Canada & the U.S.)



1-647-788-4922 (Outside Canada and the U.S.)



(Please dial in 15 minutes before the call begins)






Webcast:
A live audio webcast and presentation of the results can be accessed at:



http://neptunecorp.com/en/investors/events-presentations/



A replay of the call will be available for replay two hours after the call's completion, until November 12, 2016. The telephone numbers to access the replay of the call are 1-416-621-4642 or 1-800-585-8367 (toll-free), Conference ID 86779865. The archive of the webcast, along with its accompanying presentation, will also be made available immediately in the Investors section of Neptune's website under Investor Events and Presentations. About Neptune Technologies & Bioressources Inc.
Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers a variety of specialty ingredients, including premium krill oil manufactured in our state-of-the art facility and a variety of other marine oils, seed oils and specialty ingredients. Neptune also offers its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. Oceano3 brand is also sold in bulk to unbranded distributors. The Company's head office is located in Laval, Quebec. Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 48% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.





Neptune Contact:
Mario Paradis
VP & CFO
1.450.687.2262
[email protected]
www.neptunecorp.com
James Carbonara
Hayden IR
1.646.755.4712
[email protected]
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 14.57
NEPT's PE Ratio is ranked higher than
86% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. NEPT: 14.57 )
Ranked among companies with meaningful PE Ratio only.
NEPT' s PE Ratio Range Over the Past 10 Years
Min: 10  Med: 14.4 Max: 965
Current: 14.57
10
965
PE Ratio without NRI 14.57
NEPT's PE Ratio without NRI is ranked higher than
87% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. NEPT: 14.57 )
Ranked among companies with meaningful PE Ratio without NRI only.
NEPT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10  Med: 14.4 Max: 99999999.99
Current: 14.57
10
99999999.99
PB Ratio 1.24
NEPT's PB Ratio is ranked higher than
87% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NEPT: 1.24 )
Ranked among companies with meaningful PB Ratio only.
NEPT' s PB Ratio Range Over the Past 10 Years
Min: 1.21  Med: 4.89 Max: 37.1
Current: 1.24
1.21
37.1
PS Ratio 2.64
NEPT's PS Ratio is ranked higher than
88% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. NEPT: 2.64 )
Ranked among companies with meaningful PS Ratio only.
NEPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 7.77 Max: 34.17
Current: 2.64
1.56
34.17
EV-to-EBIT 41.04
NEPT's EV-to-EBIT is ranked lower than
63% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NEPT: 41.04 )
Ranked among companies with meaningful EV-to-EBIT only.
NEPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -223.9  Med: -12.4 Max: 1664.6
Current: 41.04
-223.9
1664.6
EV-to-EBITDA 16.74
NEPT's EV-to-EBITDA is ranked higher than
54% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NEPT: 16.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
NEPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -492.1  Med: -15.4 Max: 111.8
Current: 16.74
-492.1
111.8
EV-to-Revenue 2.39
NEPT's EV-to-Revenue is ranked higher than
87% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. NEPT: 2.39 )
Ranked among companies with meaningful EV-to-Revenue only.
NEPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 7.9 Max: 35.4
Current: 2.39
1.7
35.4
PEG Ratio 0.13
NEPT's PEG Ratio is ranked higher than
97% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. NEPT: 0.13 )
Ranked among companies with meaningful PEG Ratio only.
NEPT' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 6.38 Max: 69.98
Current: 0.13
0
69.98
Current Ratio 2.46
NEPT's Current Ratio is ranked lower than
74% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NEPT: 2.46 )
Ranked among companies with meaningful Current Ratio only.
NEPT' s Current Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.67 Max: 12.42
Current: 2.46
0.4
12.42
Quick Ratio 1.48
NEPT's Quick Ratio is ranked lower than
80% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NEPT: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
NEPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.91 Max: 12.42
Current: 1.48
0.2
12.42
Days Inventory 195.96
NEPT's Days Inventory is ranked lower than
64% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NEPT: 195.96 )
Ranked among companies with meaningful Days Inventory only.
NEPT' s Days Inventory Range Over the Past 10 Years
Min: 58.23  Med: 138.01 Max: 272.09
Current: 195.96
58.23
272.09
Days Sales Outstanding 105.08
NEPT's Days Sales Outstanding is ranked lower than
77% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. NEPT: 105.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.93  Med: 104.24 Max: 159.39
Current: 105.08
77.93
159.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.80
NEPT's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NEPT: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NEPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.5  Med: -15.55 Max: -6.2
Current: -14.8
-30.5
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.73
NEPT's Price-to-Tangible-Book is ranked higher than
82% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NEPT: 1.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NEPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.86  Med: 6.89 Max: 42.54
Current: 1.73
1.86
42.54
Price-to-Median-PS-Value 0.34
NEPT's Price-to-Median-PS-Value is ranked higher than
90% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NEPT: 0.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NEPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1 Max: 14.4
Current: 0.34
0.13
14.4
Price-to-Graham-Number 1.07
NEPT's Price-to-Graham-Number is ranked higher than
85% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. NEPT: 1.07 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NEPT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.15  Med: 1.71 Max: 8.39
Current: 1.07
1.15
8.39
Earnings Yield (Greenblatt) % 2.44
NEPT's Earnings Yield (Greenblatt) % is ranked higher than
83% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NEPT: 2.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NEPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.5  Med: -5.2 Max: 2.7
Current: 2.44
-26.5
2.7

More Statistics

Revenue (TTM) (Mil) $31.56
EPS (TTM) $ 0.05
Beta0.39
Short Percentage of Float6.63%
52-Week Range $0.70 - 1.53
Shares Outstanding (Mil)78.64

Analyst Estimate

Mar18 Mar19 Mar20
Revenue (Mil $) 22 23 29
EPS ($) -0.03 -0.01 0.02
EPS without NRI ($) -0.03 -0.01 0.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017 
Acasti Pharma Reports Second Quarter 2017 Financial Results Oct 11 2016 
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil® Oct 07 2016 
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and E Oct 03 2016 
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 20 Sep 28 2016 
NEPTUNE Introduces NKO(R) Omega Plus, a New and Innovative Krill Oil Product with one of the Highest Sep 15 2016 
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data Sep 15 2016 
Neptune to Hold Conference Call to Discuss First Quarter Results for the Period Ended May 31, 2016 Jun 30 2016 
Neptune Announces Fourth Quarter and Fiscal Year Results May 25 2016 
Acasti Announces Fourth Quarter and Fiscal Year Results May 25 2016 

More From Other Websites
Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q1, 2018 By the Numbers :... Sep 13 2017
Acasti Pharma Grants Stock Options Aug 31 2017
Neptune Technologies & Bioresources, Inc.: Price momentum supported by strong fundamentals Aug 18 2017
Neptune Announces the Election of its Directors Aug 17 2017
Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other... Aug 16 2017
Investor Network: Neptune Technologies & Bioressources Inc. to Host Earnings Call Aug 15 2017
Acasti Pharma Reports First Quarter FY 2018 Financial Results Aug 14 2017
Neptune Announces First Quarter Results Aug 14 2017
Neptune Announces Resignation of Pierre Fitzgibbon as a Director and the Appointment of John Moretz... Aug 08 2017
Neptune to Hold Conference Call to Discuss the Transaction with Aker BioMarine Aug 08 2017
Aker BioMarine and Neptune Announce Closing of $US34 Million Transaction to Accelerate Business and... Aug 08 2017
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under... Jul 28 2017
Neptune Receives Nasdaq Notification Regarding Minimum Bid Requirements Jul 27 2017
Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended... Jul 25 2017
Featured Company News - Opexa Therapeutics and Acer Therapeutics Announced Merger Agreement Followed... Jul 05 2017
CORRECTION: Acasti Pharma Grants Stock Options Jun 16 2017
Acasti Pharma To Present at Upcoming International Industry Conferences Jun 12 2017
Neptune Announces 4-Month Period and 13-Month Period Results Jun 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}